It has been shown that KLF6 expression is upregulated in the intestinal tissue of IBD patients and animal models [46], and its chromatin accessibility in MBCs is reduced by IFN-blocking antibody treatment [47]. Here, KLF6 is linked to inflammatory bowel disease.